Methyluracil (Tablets, Ointment, Suppositories) Instructions for Use

Instructions
Dosage forms

ATC Code

D11AX (Other drugs used in dermatology)

Active Substance

Dioxomethyltetrahydropyrimidine

Clinical-Pharmacological Group

A drug improving trophism and tissue regeneration, for external use

Pharmacotherapeutic Group

Other drugs used in dermatology

Pharmacological Action

An immunostimulating agent. It promotes the normalization of nucleic acid metabolism, accelerates the processes of cellular regeneration in wounds, accelerates the growth and granulation maturation of tissue and epithelialization (including in rapidly proliferating cells of the gastrointestinal tract mucosa), stimulates erythro- and leukopoiesis, cellular and humoral factors of immunity.

It has anabolic activity and anti-inflammatory action. When applied externally, it also has a photoprotective effect.

Indications

For oral administration: leukopenia (mild forms, including those resulting from chemotherapy of malignant neoplasms, during X-ray and radiation therapy), agranulocytic angina, alimentary-toxic aleukia, anemia, thrombocytopenia, benzene intoxication, radiation sickness, convalescence (after severe infections), gastric and duodenal ulcer, slow-healing wounds, burns, bone fractures, hepatitis, pancreatitis.

For external use: slow-healing wounds, skin erosions and ulcers, cracks of the skin of the mammary glands and anus, photodermatitis, bone fractures, burns (thermal, chemical, radiation), bullous dermatitis; for prophylaxis to reduce skin reactions during irradiation of neoplasms with low radiosensitivity, to reduce radioepithelitis and late adhesions of the vaginal walls (occlusion) – in case of radiation therapy for genital neoplasms.

For topical use: proctitis, sigmoiditis, ulcerative colitis.

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
D64.9	Anemia, unspecified
D69.6	Thrombocytopenia, unspecified
D70	Agranulocytosis
J03	Acute tonsillitis
K25	Gastric ulcer
K26	Duodenal ulcer
K27	Peptic ulcer
K51	Ulcerative colitis
K52	Other noninfectious gastroenteritis and colitis
K62.8	Other specified diseases of anus and rectum (including proctitis)
K73	Chronic hepatitis, not elsewhere classified
K86	Other diseases of pancreas
L56.2	Photocontact dermatitis [berloque dermatitis]
L89	Decubitus ulcer and pressure area
L98.4	Chronic skin ulcer, not elsewhere classified
T14.1	Open wound of unspecified body region
T14.2	Fracture in unspecified part of body
T30	Burns and corrosions of unspecified body region
T52.1	Benzene
T64	Toxic effect of aflatoxin and other mycotoxins contaminating foodstuffs
T66	Unspecified effects of radiation (radiation sickness)
Y43.1	Antineoplastic antimetabolites
Y43.2	Antineoplastic natural products
Y43.3	Other antineoplastic drugs
Y84.2	Radiological procedure and radiotherapy
Z54	Convalescence

ICD-11 code	Indication
3A9Z	Anemias or other diseases of the red blood cells, unspecified
3B64.Z	Thrombocytopenia, unspecified
4B00	Quantitative defects of neutrophils
4B00.00	Constitutional neutropenia
4B00.01	Acquired neutropenia
8E61.0	Radiation-induced brain injury
8E61.1	Radiation-induced spinal cord injury
CA03.Z	Acute tonsillitis, unspecified
DA42.81	Radiation gastritis
DA42.8Z	Gastritis due to external causes, unspecified
DA51.53	Radiation duodenitis
DA51.5Z	Duodenitis due to external causes, unspecified
DA60.Z	Gastric ulcer, unspecified
DA61	Peptic ulcer of unspecified site
DA63.Z	Duodenal ulcer, unspecified
DB33.2Z	Allergic or alimentary colitis, unspecified
DB33.4Y	Other specified colitis or proctitis caused by external agents
DB33.4Z	Colitis or proctitis caused by external agents, unspecified
DB70.Z	Infections of anal and rectal regions, unspecified
DB72.Z	Some specified diseases of the anal canal, unspecified
DB97.2	Chronic hepatitis, not elsewhere classified
DC30.Z	Cystic disease of pancreas, unspecified
DC32.Z	Chronic pancreatitis, unspecified
DC35.Z	Other specified diseases of pancreas, unspecified
DC3Z	Diseases of pancreas, unspecified
DD71.Z	Ulcerative colitis, unspecified
DE2Z	Diseases of the digestive system, unspecified
EA40	Tropical phagedenic ulcer
EF60	Ischemic ulceration of the skin
EG61	Infections of the anus or perianal skin
EH90.Z	Pressure ulcer of unspecified degree
EK20	Photoallergic reaction to fragrances or cosmetic products
EM0Z	Unspecified skin disorder
ME60.2	Ulcerative skin lesion of unspecified nature
ND56.1	Open wound of unspecified body region
ND56.2	Fracture in unspecified part of body
NE11	Burn of unspecified body region
NE61	Toxic effect of poisonous substances, chiefly nonmedicinal, not elsewhere classified
NF00	Exposure to radiation, not elsewhere classified
PK81.C	Radiotherapy causing injury or harm in the course of therapeutic use
PL00	Drugs, medicaments or biological substances causing injury or harm in therapeutic use
QB7Z	Convalescence, unspecified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Suppositories

Rectally. Adults: 0.5-1 g 3-4 times/day; children aged 8-15 years: 500 mg/day. The course of treatment is from 7 days to 4 months.

Ointment

Orally, during or after meals, 500 mg 4 times/day (if necessary – up to 6 times/day); children from 3 to 8 years: 250 mg, over 8 years: 250-500 mg 3 times/day. The course for gastrointestinal diseases is 30-40 days; in other cases, it may be shorter.

For external use, the dosage regimen is set individually, depending on the dosage form used. The frequency of dressing changes depends on the depth and area of the wound surface, the intensity of exudation, and the presence of necrotic masses.

Rectally used in adults 0.5-1 g 3-4 times/day; in children aged 3-8 years – 250 mg/day, in children aged 8-15 years – 500 mg/day. The course of treatment is from 1 week to 4 months.

Tablets

Orally, during or after meals.

Adults – 500 mg 4 times a day (if necessary – up to 6 times a day, maximum daily dose – 3 g);

Children from 3 to 8 years – 250 mg 3 times a day (maximum daily dose – 750 mg);

Children from 8 years to 14 years – 250-500 mg 3 times a day (maximum daily dose – 1.5 g).

The course for diseases of the gastrointestinal tract is 30-40 days; in other cases, it may be shorter.

Adverse Reactions

Possible allergic reactions; when taken orally – headache, dizziness, heartburn.

With external use burning at the site of application of the drug.

Contraindications

Hypersensitivity to dioxomethyltetrahydropyrimidine; leukemia (leukemic forms, especially myeloid), lymphogranulomatosis, hemoblastoses, malignant diseases of the bone marrow, children under 3 years of age.

For external and topical use: excessive granulations in the wound.

Use in Pregnancy and Lactation

If it is necessary to use during pregnancy and breastfeeding, the expected benefit of therapy for the mother and the possible risk to the fetus should be taken into account.

Pediatric Use

Contraindicated for use in children under 3 years of age.

Special Precautions

Drugs containing Dioxomethyltetrahydropyrimidine should be used strictly in accordance with the indications.

Drug Interactions

Enhances the anti-radiation effect of cystamine.

For external use, it is compatible with applications of antibacterial and antiseptic agents.

Simultaneous use of corticosteroids reduces the effectiveness of this agent for external and topical use.

Storage Conditions

Store at 2°C (36°F) to 15°C (59°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Methyluracil [Altayvitamins, JSC (Russia)]
Rectal suppositories 500 mg: 10 pcs.

Marketing Authorization Holder

Altayvitamins, JSC (Russia)

Dosage Form

Methyluracil

Rectal suppositories 500 mg: 10 pcs.

Dosage Form, Packaging, and Composition

Rectal suppositories	1 supp.
Methyluracil	500 mg

5 pcs. – contour cell packs (2) – cardboard packs.

Methyluracil [Atoll LLC (Russia)]
Ointment for topical and external use 10%: 25 g or 30 g tubes

Marketing Authorization Holder

Atoll LLC (Russia)

Manufactured By

Ozon, LLC (Russia)

Dosage Form

Methyluracil

Ointment for topical and external use 10%: 25 g or 30 g tubes

Dosage Form, Packaging, and Composition

Ointment for topical and external use from white with a yellowish tint to light yellow in color, with a characteristic odor, homogeneous.

	100 g
Dioxomethyltetrahydropyrimidine (methyluracil)	10 g

Excipients : petrolatum – 45 g, lanolin – 31.5 g, purified water – 13.5 g.

25 g – tubes – cardboard packs.
30 g – tubes – cardboard packs.

Methyluracil [Biosintez, PJSC (Russia)]
Ointment for topical and external use 10%: tube 25 g

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Methyluracil

Ointment for topical and external use 10%: tube 25 g

Dosage Form, Packaging, and Composition

Ointment for topical and external use 10%	1 g
Methyluracil	100 mg

25 g – aluminum tubes (1) – cardboard packs.

Methyluracil [Biosintez, PJSC (Russia)]
Rectal suppositories 500 mg: 10 pcs.

Marketing Authorization Holder

Biosintez, PJSC (Russia)

Dosage Form

Methyluracil

Rectal suppositories 500 mg: 10 pcs.

Dosage Form, Packaging, and Composition

Rectal suppositories white or white with a yellowish tint.

	1 supp.
Dioxomethyltetrahydropyrimidine (methyluracil)	500 mg

Excipients : hard fat.

5 pcs. – contour cell packs (2) – cardboard packs.

Methyluracil [Biopharmkombinat, LLC (Russia)]
Rectal suppositories 500 mg: 5 or 10 pcs.

Marketing Authorization Holder

Biopharmkombinat, LLC (Russia)

Dosage Form

Methyluracil

Rectal suppositories 500 mg: 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Rectal suppositories white or white with a yellowish or brownish tint, torpedo-shaped.

	1 supp.
Dioxomethyltetrahydropyrimidine (methyluracil)	500 mg

Excipients : hard fat (Witepsol W35 or Suppocire NAI25A) – 1.8 g.

5 pcs. – contour cell packs (1) – cardboard packs.
5 pcs. – contour cell packs (2) – cardboard packs.

Methyluracil [West, LLC (Russia)]
Ointment for topical and external use 10%: jars or tubes 25 g, 30 g, 40 g, or 50 g

Marketing Authorization Holder

West, LLC (Russia)

Manufactured By

Samaramedprom, OJSC (Russia)

Dosage Form

Methyluracil

Ointment for topical and external use 10%: jars or tubes 25 g, 30 g, 40 g, or 50 g

Dosage Form, Packaging, and Composition

Ointment for topical and external use from light yellow to yellow in color, homogeneous, with a characteristic odor.

	100 g
Dioxomethyltetrahydropyrimidine (methyluracil)	10 g

Excipients : petrolatum, anhydrous lanolin, purified water.

25 g – jars (1) – cardboard packs.
30 g – jars (1) – cardboard packs.
40 g – jars (1) – cardboard packs.
50 g – jars (1) – cardboard packs.
25 g – aluminum tubes (1) – cardboard packs.
30 g – aluminum tubes (1) – cardboard packs.
40 g – aluminum tubes (1) – cardboard packs.
50 g – aluminum tubes (1) – cardboard packs.

Methyluracil [Vita Line, LLC (Russia)]
Ointment for topical and external use 10%: tubes 15 g, 20 g, 25 g, 30 g, or 40 g

Marketing Authorization Holder

Vita Line, LLC (Russia)

Manufactured By

Tula Pharmaceutical Factory, LLC (Russia)

Dosage Form

Methyluracil

Ointment for topical and external use 10%: tubes 15 g, 20 g, 25 g, 30 g, or 40 g

Dosage Form, Packaging, and Composition

Ointment for topical and external use from light yellow to yellow in color, homogeneous.

	100 g
Dioxomethyltetrahydropyrimidine (methyluracil)	10 g

Excipients : petrolatum – 45 g, anhydrous lanolin – 31.5 g, purified water – 13.5 g.

15 g – tubes (1) – cardboard packs.
20 g – tubes (1) – cardboard packs.
25 g – tubes (1) – cardboard packs.
30 g – tubes (1) – cardboard packs.
40 g – tubes (1) – cardboard packs.

Methyluracil [Dalkhimpharm, JSC (Russia)]
Rectal suppositories 500 mg: 10 pcs.

Marketing Authorization Holder

Dalkhimpharm, JSC (Russia)

Dosage Form

Methyluracil

Rectal suppositories 500 mg: 10 pcs.

Dosage Form, Packaging, and Composition

Rectal suppositories white or white with a yellowish or creamy tint, torpedo-shaped.

	1 supp.
Methyluracil	500 mg

Excipients : suppository base: hard fat, type A or E – sufficient quantity to obtain a suppository weighing 2.3 g.

5 pcs. – contour cell packs (2) – cardboard packs.

Methyluracil [Zelenaya Dubrava, CJSC (Russia)]
Ointment for external use 10%: tube 25 g

Marketing Authorization Holder

Zelenaya Dubrava, CJSC (Russia)

Dosage Form

Methyluracil

Ointment for external use 10%: tube 25 g

Dosage Form, Packaging, and Composition

Ointment for external use	1 g
Dioxomethyltetrahydropyrimidine (methyluracil)	100 mg

25 g – aluminum tubes (1) – cardboard packs.

Methyluracil [Ivanovo Pharmaceutical Factory PJSC (Russia)]
Ointment for topical and external use 10%: 25 g, 30 g, or 50 g jars or tubes

Marketing Authorization Holder

Ivanovo Pharmaceutical Factory PJSC (Russia)

Dosage Form

Methyluracil

Ointment for topical and external use 10%: 25 g, 30 g, or 50 g jars or tubes

Dosage Form, Packaging, and Composition

Ointment for topical and external use from light yellow to yellow in color, with a characteristic odor.

	100 g
Dioxomethyltetrahydropyrimidine (methyluracil)	10 g

Excipients: petrolatum – 45 g, anhydrous lanolin – 31.5 g, purified water – 13.5 g.

25 g – jars (1) – cardboard packs.
30 g – jars (1) – cardboard packs.
50 g – jars (1) – cardboard packs.
25 g – aluminum tubes (1) – cardboard packs.
30 g – aluminum tubes (1) – cardboard packs.
50 g – aluminum tubes (1) – cardboard packs.

Methyluracil [Murom Instrument-Making Plant, JSC (Russia)]
Ointment for topical and external use 10%: tubes 25 g

Marketing Authorization Holder

Murom Instrument-Making Plant, JSC (Russia)

Dosage Form

Methyluracil

Ointment for topical and external use 10%: tubes 25 g

Dosage Form, Packaging, and Composition

Ointment for topical and external use from white with a yellowish tint to light yellow in color.

	100 g
Dioxomethyltetrahydropyrimidine (methyluracil)	10 g

Excipients: hydrous lanolin, petrolatum.

25 g – aluminum tubes (1) – cardboard packs.

Methyluracil [Nizhpharm JSC (Russia)]
Ointment for topical and external use 10%: tubes 25 g

Marketing Authorization Holder

Nizhpharm JSC (Russia)

Dosage Form

Methyluracil

Ointment for topical and external use 10%: tubes 25 g

Dosage Form, Packaging, and Composition

Ointment for topical and external use from white with a yellowish tint to light yellow in color, homogeneous.

	1 g
Dioxomethyltetrahydropyrimidine (methyluracil)	100 mg

Excipients: petrolatum, lanolin, purified water.

25 g – tubes (1) – cardboard packs.

Methyluracil [Nizhpharm JSC (Russia)]
Rectal suppositories 500 mg: 10 pcs.

Marketing Authorization Holder

Nizhpharm JSC (Russia)

Dosage Form

Methyluracil

Rectal suppositories 500 mg: 10 pcs.

Dosage Form, Packaging, and Composition

Rectal suppositories white or white with a yellowish or creamy tint, torpedo-shaped; the appearance of a coating on the surface of the suppository and the presence of an air rod and a funnel-shaped depression on the cut are allowed.

	1 supp.
Dioxomethyltetrahydropyrimidine (methyluracil)	500 mg

Excipients: hard fat (witepsol (grades H15, W35)), Suppocire (grades NA15, NAS50).

5 pcs. – contour cell packs (2) – cardboard packs.

Methyluracil [Novosibkhimpharm, JSC (Russia)]
Tablets 500 mg: 50 pcs.

Marketing Authorization Holder

Novosibkhimpharm, JSC (Russia)

Dosage Form

Methyluracil

Tablets 500 mg: 50 pcs.

Dosage Form, Packaging, and Composition

Tablets	1 tab.
Dioxomethyltetrahydropyrimidine (methyluracil)	500 mg

10 pcs. – contour cell packs (5) – cardboard packs.

Methyluracil [Obnovlenie Pfc, JSC (Russia)]
Tablets 500 mg: 50, 100, or 200 pcs.

Marketing Authorization Holder

Obnovlenie Pfc, JSC (Russia)

Dosage Form

Methyluracil

Tablets 500 mg: 50, 100, or 200 pcs.

Dosage Form, Packaging, and Composition

Tablets white, round, flat-cylindrical, with a bevel, with a score on one side and with or without an engraving “R” on the other.

	1 tab.
Dioxomethyltetrahydropyrimidine	500 mg

Ointment for topical and external use yellowish, yellowish-brown or greenish-brown in color, with a characteristic odor.

	100 g
Dioxomethyltetrahydropyrimidine (methyluracil)	10 g

Excipients: petrolatum, anhydrous lanolin, purified water.

25 g – aluminum tubes (1) – cardboard packs.

Methyluracil [Tula Pharmaceutical Factory, LLC (Russia)]
Ointment for topical and external use 10%: 25 g or 30 g jars or tubes

Marketing Authorization Holder

Tula Pharmaceutical Factory, LLC (Russia)

Dosage Form

Methyluracil

Ointment for topical and external use 10%: 25 g or 30 g jars or tubes

Dosage Form, Packaging, and Composition

Ointment for topical and external use from light yellow to yellow in color.

	100 g
Dioxomethyltetrahydropyrimidine (methyluracil)	10 g

Excipients: petrolatum – 45 g, anhydrous lanolin – 31.5 g, purified water – 13.5 g.

25 g – polyethylene jars (1) – cardboard packs.
30 g – polyethylene jars (1) – cardboard packs.
25 g – polyethylene terephthalate jars (1) – cardboard packs.
30 g – polyethylene terephthalate jars (1) – cardboard packs.
25 g – orange glass jars (1) – cardboard packs.
25 g – aluminum tubes (1) – cardboard packs.
30 g – aluminum tubes (1) – cardboard packs.
25 g – polyethylene jars (30) – cardboard boxes (for hospitals).
25 g – polyethylene jars (60) – cardboard boxes (for hospitals).
30 g – polyethylene jars (30) – cardboard boxes (for hospitals).
30 g – polyethylene jars (60) – cardboard boxes (for hospitals).
25 g – polyethylene terephthalate jars (30) – cardboard boxes (for hospitals).
25 g – polyethylene terephthalate jars (60) – cardboard boxes (for hospitals).
30 g – polyethylene terephthalate jars (30) – cardboard boxes (for hospitals).
30 g – polyethylene terephthalate jars (60) – cardboard boxes (for hospitals).
25 g – orange glass jars (30) – cardboard boxes (for hospitals).
25 g – orange glass jars (60) – cardboard boxes (for hospitals).
25 g – aluminum tubes (40) – cardboard boxes (for hospitals).
25 g – aluminum tubes (99) – cardboard boxes (for hospitals).
30 g – aluminum tubes (40) – cardboard boxes (for hospitals).
30 g – aluminum tubes (99) – cardboard boxes (for hospitals).

Methyluracil [Tula Pharmaceutical Factory, LLC (Russia)]
Rectal suppositories 500 mg: from 1 to 100 pcs.

Marketing Authorization Holder

Tula Pharmaceutical Factory, LLC (Russia)

Dosage Form

Methyluracil

Rectal suppositories 500 mg: from 1 to 100 pcs.

Dosage Form, Packaging, and Composition

Rectal suppositories white or white with a yellowish or creamy tint, torpedo-shaped; the appearance of a white coating on the surface of the suppository is allowed; on the longitudinal section – homogeneous, without inclusions, the presence of an air rod or a funnel-shaped depression is allowed.

	1 supp.
Dioxomethyltetrahydropyrimidine (methyluracil)	500 mg

Excipients: hard fat (witepsol (grades H15, W35), suppocire (grades NA15, NAS50)) – to obtain a suppository weighing 2.3 g.

From 1 to 10 pcs. – contour cell packs (from 1 to 10 pcs.) – cardboard packs.

Methyluracil [Usolye-Sibirskiy Chemical and Pharmaceutical Plant, JSC (Russia)]
Ointment for topical and external use 10%: tubes 25 g or 30 g, jars 15 g, 20 g, 25 g, or 30 g

Marketing Authorization Holder

Usolye-Sibirskiy Chemical and Pharmaceutical Plant, JSC (Russia)

Dosage Form

Methyluracil

Ointment for topical and external use 10%: tubes 25 g or 30 g, jars 15 g, 20 g, 25 g, or 30 g

Dosage Form, Packaging, and Composition

Ointment for topical and external use yellowish in color, homogeneous.

	100 g
Dioxomethyltetrahydropyrimidine (methyluracil)	10 g

Excipients: petrolatum – 45 g, anhydrous lanolin – 31.5 g, purified water – 13.5 g.

15 g – jars (1) – cardboard packs.
20 g – jars (1) – cardboard packs.
25 g – jars (1) – cardboard packs.
30 g – jars (1) – cardboard packs.
25 g – tubes (1) – cardboard packs.
30 g – tubes (1) – cardboard packs.
Tubes from 9 to 300 pcs. – cardboard boxes (for hospitals).
Jars from 9 to 300 pcs. – cardboard boxes (for hospitals).

Methyluracil [Usolye-Sibirskiy Chemical and Pharmaceutical Plant, JSC (Russia)]
Tablets 500 mg: 10, 20, 30, 50 or 100 pcs.

Marketing Authorization Holder

Usolye-Sibirskiy Chemical and Pharmaceutical Plant, JSC (Russia)

Dosage Form

Methyluracil

Tablets 500 mg: 10, 20, 30, 50 or 100 pcs.

Dosage Form, Packaging, and Composition

Tablets white, flat-cylindrical in shape, with a bevel and a score.

	1 tab.
Dioxomethyltetrahydropyrimidine (methyluracil)	500 mg

Excipients: potato starch – 120.5 mg, sodium carboxymethyl starch – 21 mg, povidone K17 – 37 mg, tween-80 (polysorbate) – 0.5 mg, calcium stearate (octadecanoate) – 7 mg, talc – 14 mg.

Tablet weight 700 mg

10 pcs. – blister packs (1) – cardboard packs.
10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (5) – cardboard packs.
30 pcs. – jars (1) – cardboard packs.
50 pcs. – jars (1) – cardboard packs.
100 pcs. – jars (1) – cardboard packs.
10 pcs. – blister packs (100) – group packaging (for hospitals).
10 pcs. – blister packs (200) – group packaging (for hospitals).
10 pcs. – blister packs (400) – group packaging (for hospitals).
10 pcs. – blister packs (500) – group packaging (for hospitals).
10 pcs. – blister packs (600) – group packaging (for hospitals).
10 pcs. – blister packs (1000) – group packaging (for hospitals).

Methyluracil [Usolye-Sibirskiy Chemical and Pharmaceutical Plant, JSC (Russia)]
Rectal suppositories 500 mg: 10 pcs.

Marketing Authorization Holder

Usolye-Sibirskiy Chemical and Pharmaceutical Plant, JSC (Russia)

Dosage Form

Methyluracil

Rectal suppositories 500 mg: 10 pcs.

Dosage Form, Packaging, and Composition

Rectal suppositories of a torpedo-like shape, white or white with a yellowish or creamy tint. The presence of an air core on the cut and a funnel-shaped depression is allowed.

	1 supp.
Dioxomethyltetrahydropyrimidine	500 mg

Excipients: solid fat (witepsol grade H 15; witepsol W 35 (3:1), suppocire grade NA 15, suppocire NAS 50 (3:1)) – 1800 mg.

5 pcs. – blister pack (2) – cardboard packs.

Methyluracil [Formula-FR, LLC (Russia)]
Ointment for topical and external use 10%: tubes 15 g, 20 g, 25 g, 30 g, or 40 g

Marketing Authorization Holder

Formula-FR, LLC (Russia)

Manufactured By

Tula Pharmaceutical Factory, LLC (Russia)

Dosage Form

Methyluracil

Ointment for topical and external use 10%: tubes 15 g, 20 g, 25 g, 30 g, or 40 g

Dosage Form, Packaging, and Composition

Ointment for topical and external use homogeneous, from light yellow to yellow in color.

	100 g
Dioxomethyltetrahydropyrimidine	10 g

Excipients: petrolatum – 45 g, anhydrous lanolin – 31.5 g, purified water – 13.5 g.

15 g – tubes (1) – cardboard packs.
20 g – tubes (1) – cardboard packs.
25 g – tubes (1) – cardboard packs.
30 g – tubes (1) – cardboard packs.
40 g – tubes (1) – cardboard packs.

Methyluracil [YUGPHARM, LLC (Russia)]
Rectal suppositories 500 mg: 10 pcs.

Marketing Authorization Holder

YUGPHARM, LLC (Russia)

Dosage Form

Methyluracil

Rectal suppositories 500 mg: 10 pcs.

Dosage Form, Packaging, and Composition

Rectal suppositories white or white with a yellowish or creamy tint, torpedo-shaped.

	1 supp.
Dioxomethyltetrahydropyrimidine	500 mg

Excipients: solid fat (witepsol W35 or suppocire NAI25A) – 1.8 g.

5 pcs. – blister packs (2) – cardboard packs.

Methyluracil ointment 10% [St. Petersburg Research Institute of Vaccines and Sera of the FMBA, FSUE (Russia)]
Ointment for topical and external use 10%: 25 g tubes, 25 g, 50 g, 75 g jars

Marketing Authorization Holder

St. Petersburg Research Institute of Vaccines and Sera of the FMBA, FSUE (Russia)

Dosage Form

Methyluracil ointment 10%

Ointment for topical and external use 10%: 25 g tubes, 25 g, 50 g, 75 g jars

Dosage Form, Packaging, and Composition

Ointment for topical and external use 10%	1 g
Methyluracil	100 mg

25 g – aluminum tubes (1) – cardboard packs.
25 g – dark glass jars (1) – cardboard packs.
50 g – dark glass jars (1) – cardboard packs.
75 g – dark glass jars (1) – cardboard packs.

Methyluracil Renewal [Obnovlenie Pfc, JSC (Russia)]
Ointment for topical and external use 10%: tubes or jars 15 g or 25 g

Marketing Authorization Holder

Obnovlenie Pfc, JSC (Russia)

Dosage Form

Methyluracil Renewal

Ointment for topical and external use 10%: tubes or jars 15 g or 25 g

Dosage Form, Packaging, and Composition

Ointment for topical and external use

	1 g
Dioxomethyltetrahydropyrimidine	100 mg

15 g – jars – cardboard packs – By prescription
15 g – tubes – cardboard packs – By prescription
25 g – jars – cardboard packs – By prescription
25 g – tubes – cardboard packs – By prescription

Methyluracil-AKOS [Sintez PJSC (Russia)]
Ointment for external use 10%: tube 25 g